GRAIL’s Galleri Test Shows Mixed Results with Significant Drop in Stage IV Cancer

In a development highlighting both the potential and the hurdles of early cancer detection, GRAIL announced full results from its NHS-Galleri trial at the 2026 ASCO Annual Meeting. According to reports, the Galleri test successfully reduced Stage IV cancer diagnoses by 22% in the second screening round and 26% in the third round. However, the trial did not meet its primary aggregate endpoint of reducing combined Stage III and IV cancers, though it did drive a 16% increase in early-stage (Stage I-II) diagnoses compared to standard care.

These results arrive amid intensifying competition in the biotech sector, with peers like Exact Sciences and Guardant Health racing to refine multi-cancer early detection (MCED) blood tests. Per market data, investors are weighing the clinical utility against the cost-effectiveness of these screenings; prior ASCO reports suggest that early-stage intervention significantly lowers long-term healthcare expenditures compared to late-stage treatments. The 26% reduction in Stage IV cases represents a vital clinical milestone despite the missed aggregate targets.

Looking ahead, market participants will monitor how these mixed findings impact the test's adoption within national health frameworks. Regarding broader catalysts, the Core PCE Price Index data released on May 28, 2026, continues to influence risk sentiment across the high-growth biotech landscape. Investors should also watch for upcoming regulatory commentary or potential FDA submissions that could define the commercial trajectory of the Galleri platform in the coming quarters.